Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer

Share This Post

August 2021: The FDA granted amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, accelerated approval for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.

The Guardant360® CDx (Guardant Health, Inc.) has also been approved by the FDA as a companion diagnostic for amivantamab-vmjw.

CHRYSALIS, a multicenter, non-randomized, open label, multicohort clinical trial (NCT02609776) that included patients with locally advanced or metastatic NSCLC who had EGFR exon 20 insertion mutations, was used to gain approval. Efficacy was assessed in 81 patients with advanced NSCLC who had EGFR exon 20 insertion mutations and had progressed after platinum-based treatment. Amivantamab-vmjw was given to patients once a week for four weeks, then every two weeks until disease progression or unacceptable toxicity.

Overall response rate (ORR) according to RECIST 1.1 as assessed by blinded independent central review (BICR) and response duration were the key efficacy outcome measures. With a median response time of 11.1 months, the ORR was 40% (95 percent CI: 29 percent, 51 percent) (95 percent CI: 6.9, not evaluable).

Rash, infusion-related responses, paronychia, musculoskeletal pain, dyspnea, nausea, exhaustion, edoema, stomatitis, cough, constipation, and vomiting were the most prevalent side events (20%).

The recommended dose of amivantamab-vmjw is 1050 mg for patients with a baseline body weight of less than 80 kg and 1400 mg for those with a baseline body weight of more than 80 kg, given weekly for four weeks and then every two weeks until disease progression or unacceptable toxicity occurs.



Check details here.

Take second opinion on lung cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form